<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-26358" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Oseltamivir</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sur</surname>
            <given-names>Moushumi</given-names>
          </name>
          <aff>Baylor College of Med, TX Children Hosp</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lopez</surname>
            <given-names>Michael J.</given-names>
          </name>
          <aff>Augusta Un., Medical College of Georgia</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Baker</surname>
            <given-names>Mari B.</given-names>
          </name>
          <aff>OSF Saint Francis Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Moushumi Sur declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Michael Lopez declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mari Baker declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-26358.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Oseltamivir is an antiviral medication used to manage acute, uncomplicated influenza A or B in adult and pediatric patients, including neonates older than&#x000a0;2 weeks. For neonates&#x000a0;younger than 2&#x000a0;weeks, using oseltamivir&#x000a0;to treat influenza is considered, although the safety and efficacy in this population remain unestablished. National advisory bodies advocate the initiation of oseltamivir within 48 hours of symptom onset, particularly for individuals hospitalized with influenza or possessing significant comorbidities&#x000a0;placing them at heightened risk for complications. This activity explores oseltamivir's indications, mechanism of action, administration protocols, significant adverse effects, contraindications, monitoring strategies, and potential toxicity. The goal is to equip healthcare providers with the necessary knowledge to guide patient therapy effectively, ultimately optimizing outcomes in the combat against influenza and related viral infections.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify&#x000a0;the indications for using oseltamivir.</p></list-item><list-item><p>Evaluate&#x000a0;the mechanism of action of oseltamivir.</p></list-item><list-item><p>Assess the adverse drug reactions of&#x000a0;oseltamivir.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from oseltamivir treatment.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26358&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26358">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-26358.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Oseltamivir is appropriate for treating acute, uncomplicated influenza A or B illness in adults and pediatric patients, including neonates older than&#x000a0;2 weeks.<xref ref-type="bibr" rid="article-26358.r1">[1]</xref>&#x000a0;Neonates&#x000a0;younger than 2 weeks&#x000a0;may also receive oseltamivir for the treatment of influenza, but safety and efficacy in this population have not been established.<xref ref-type="bibr" rid="article-26358.r2">[2]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Oseltamivir has received approval from the FDA for treating and preventing both influenza A and B infections. They are indicated for managing acute, uncomplicated cases in individuals&#x000a0;2 weeks and older, provided symptoms have emerged within 48 hours. Additionally, oseltamivir is considered suitable for prophylactic use in patients 1 year and older.</p>
        <p>The American Academy of Pediatrics guidelines recommend using&#x000a0;oseltamivir to treat influenza in preterm infants, but it is not recommended for&#x000a0;chemoprophylaxis in preterm infants. Consultation with a pediatric infectious disease physician is recommended in preterm infants younger than 28 weeks.<xref ref-type="bibr" rid="article-26358.r3">[3]</xref>&#x000a0;Empiric treatment with oseltamivir can shorten the duration of illness and is recommended for healthy individuals with symptoms suggestive of influenza, even before confirmation testing if treatment is initiated within 48 hours of symptoms. Multiple national advisory bodies have endorsed using oseltamivir as soon as possible (ideally less than 48 hours after symptom onset) for patients hospitalized with influenza or significant comorbidities,&#x000a0;placing them at high risk for complications.<xref ref-type="bibr" rid="article-26358.r4">[4]</xref></p>
        <p>There is evidence that oseltamivir can have efficacy&#x000a0;in hospitalized patients up to 4 to 5 days after symptoms onset. Hence, recommendations endorse ordering oseltamivir for hospitalized patients with severe or progressive influenza or those at high risk of developing complications, regardless of symptom onset.<xref ref-type="bibr" rid="article-26358.r5">[5]</xref>&#x000a0;Individuals at increased risk for complications include children younger than 2,&#x000a0;nursing home residents,&#x000a0;adults who are obese or older than 65, pregnant women, and patients with pulmonary, liver, renal, or cardiovascular disease, malignancy, neurodevelopmental disorders, metabolic disorders, epilepsy, muscular dystrophy, and immunosuppression.</p>
        <p>
<bold>Off-Label&#x000a0;Uses</bold>
</p>
        <p>Recommendations endorsing oseltamivir as the drug of choice for treatment and prophylaxis of illness caused by avian influenza strains, including the highly pathogenic avian influenza A (H5N1), come from the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO).</p>
      </sec>
      <sec id="article-26358.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Oseltamivir is an antiviral neuraminidase inhibitor with potent and selective competitive inhibition of the influenza virus neuraminidase, an enzyme necessary for viral replication. Oseltamivir phosphate is an inactive prodrug that exerts pharmacologic activity when hydrolyzed in vivo to the active form, oseltamivir carboxylate. This activated form interferes with the release of progeny influenza virus from infected host cells and halts the spread of infection to new host cells. Oseltamivir reduces the duration of shedding and the viral titer and can shorten the length of symptoms by 0.5 to 3 days.<xref ref-type="bibr" rid="article-26358.r6">[6]</xref></p>
        <p><bold>Mechanism of Resistance:<bold>&#x000a0;</bold></bold>The mechanism of resistance of influenza viruses involves antigenic drift and shift in their surface glycoproteins. Antigenic drift is the process in which minor modifications occur in key viral epitopes through point mutations; antigenic shift results in a complete exchange of hemagglutinin (HA) or neuraminidase (NA) genes. Antigenic shift emerges mainly in influenza A viruses due to their vast animal reservoirs. Antigenic shift is a process frequently associated with the outbreak of pandemics.<xref ref-type="bibr" rid="article-26358.r7">[7]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption: </bold>Oseltamivir is an orally administrated prodrug. The oral bioavailability of oseltamivir is approximately 80%. Oral intake does not seem to impact the pharmacokinetics of oseltamivir significantly.</p>
        <p><bold>Distribution: </bold>The volume of distribution is approximately 23 to 26 liters. Oseltamivir is moderately bound to plasma proteins (42%), while oseltamivir carboxylate has poor plasma protein binding.</p>
        <p><bold>Metabolism: </bold>Hepatic carboxylesterases extensively hydrolyze oseltamivir to the active drug oseltamivir carboxylate (OC). The active metabolite, oseltamivir, is a major circulating component (95%) in plasma, and the prodrug oseltamivir accounts for only 5% of the circulating component.</p>
        <p><bold>Elimination: </bold>Osaletmevir carboxylate is eliminated (&#x0003e;99%) through renal excretion by glomerular filtration and active tubular secretion. The half-life of oseltamivir carboxylate is 6 to 10 hours, while the half-life of oseltamivir is approximately 3 hours.<xref ref-type="bibr" rid="article-26358.r8">[8]</xref></p>
      </sec>
      <sec id="article-26358.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms</bold>
</p>
        <p>Oseltamivir phosphate is administered orally, with or without meals, and is available in capsule form of&#x000a0;3 different dosages (30, 45, and 75 mg) and an oral powder for reconstitution to suspension for pediatric patients. Therapy should be initiated as early as possible, and maximum benefit is derived when started within 48 hours of the onset of illness. However, treatment must be initiated before the 48-hour window for severe illness or patients at risk of complications.</p>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p>
<bold>Seasonal Influenza A and B Treatment (5-day&#x000a0;oral course)&#x000a0;</bold>
<xref ref-type="bibr" rid="article-26358.r5">[5]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Adults: 75 mg BID</p>
          </list-item>
          <list-item>
            <p>Infants 0 to 8 months: 3 mg/kg/dose BID</p>
          </list-item>
          <list-item>
            <p>Infants 9 to 11 months: 3.5 mg/kg/dose BID</p>
          </list-item>
          <list-item>
            <p>Children 1 to 12 yrs old:
<list list-type="bullet"><list-item><p>&#x0003c;15 kg: 30 mg BID</p></list-item><list-item><p>15 kg to 23 kg: 45 mg BID</p></list-item><list-item><p>23 kg to 40 kg: 60 mg BID</p></list-item><list-item><p>&#x0003e;40 kg: 75 mg PO BID</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Patients with severe infections admitted to an intensive care unit, or immunosuppressed may require oseltamivir treatment for a prolonged indeterminate duration (more than&#x000a0;5 days).</p>
        <p>
<bold>Treatment Dosing Adjustments for Creatinine Clearance</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>CrCl 30 to 60 mL/min: 30 mg BID</p>
          </list-item>
          <list-item>
            <p>CrCl less than 30 mL/min: 30 mg daily</p>
          </list-item>
          <list-item>
            <p>Patients on hemodialysis: 30 mg after dialysis x 5 days (assumes 3 HD sessions)</p>
          </list-item>
        </list>
        <p>
<bold>Seasonal Influenza A and B Prophylaxis (7 to 10-day oral course)</bold>
<bold/>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Adults: 75 mg daily&#x000a0;<xref ref-type="bibr" rid="article-26358.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Infants 0 to 8 months: 3 mg/kg/dose daily (not indicated for under&#x000a0;3 months unless clinically critical)</p>
          </list-item>
          <list-item>
            <p>Infants 9&#x000a0;to 11 months: 3 mg/kg/dose daily</p>
          </list-item>
          <list-item>
            <p>Children 1&#x000a0;to 12 yrs old:
<list list-type="bullet"><list-item><p>&#x0003c;15 kg: 30 mg daily</p></list-item><list-item><p>15 kg to 23 kg: 45 mg daily</p></list-item><list-item><p>23 kg to 40 kg: 60 mg daily</p></list-item><list-item><p>&#x0003e;40 kg: 75 mg daily</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Prophylaxis Dosing Adjustments for Creatinine Clearance</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>CrCl 30 to 60 mL/min: 30 mg daily</p>
          </list-item>
          <list-item>
            <p>CrCl less than 30 mL/min: 30 mg every other day</p>
          </list-item>
          <list-item>
            <p>End-stage renal disease: use is not recommended</p>
          </list-item>
        </list>
        <p>While recommendations for oseltamivir include the treatment of avian influenza infections, the optimum dosage and duration of therapy are unknown for these infections.<xref ref-type="bibr" rid="article-26358.r10">[10]</xref>&#x000a0;</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment: </bold>According to the manufacturer's labeling information, no dosage adjustment is recommended in case of mild to moderate liver disease. In severe hepatic impairment (Child-Pugh class C), oseltamivir exposure (AUC) is elevated by a factor of&#x000a0;6. Use in severe hepatic impairment is not recommended.<xref ref-type="bibr" rid="article-26358.r11">[11]</xref></p>
        <p><bold>Renal impairment: </bold>The first dose should be 75 mg for patients with normal body mass. Subsequent doses should be decreased according to the degree of renal impairment. In patients on hemodialysis, reduce the oseltamivir dosage by 30 mg and an additional 30 mg after each hemodialysis session, ensuring the treatment duration does not exceed&#x000a0;5 days.<xref ref-type="bibr" rid="article-26358.r12">[12]</xref></p>
        <p><bold>Pregnancy considerations: &#x000a0;</bold>Complications of influenza during pregnancy include&#x000a0;late pregnancy loss and a decrease in mean birth weight.<xref ref-type="bibr" rid="article-26358.r13">[13]</xref>&#x000a0;Since pregnant and postpartum women are at increased risk of severe seasonal and pandemic influenza infection complications, the CDC recommends treatment and prevention with oseltamivir or zanamivir according to viral strain. Complications of influenza during pregnancy include late pregnancy loss and a decrease in mean birth weight.<xref ref-type="bibr" rid="article-26358.r14">[14]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>Limited&#x000a0;clinical information suggests that oseltamivir and its active metabolites are excreted into breast milk in trace amounts. Oseltamivir is a former FDA pregnancy class C.&#x000a0;A maternal dose of 150 mg of oseltamivir daily produces low levels in milk and&#x000a0;is not anticipated to cause adverse&#x000a0;drug reactions in breastfed infants.<xref ref-type="bibr" rid="article-26358.r15">[15]</xref></p>
        <p><bold>Pediatric patients:&#x000a0;</bold>For pediatric patients, administer oral suspension (6 mg/mL) based on weight. Ensure accurate dosing for&#x000a0;infants. Use oral suspension if swallowing capsules is difficult. Postexposure prophylaxis lasts&#x000a0;10 days, while seasonal prevention&#x000a0;is up to 6 weeks (or 12 weeks in immunocompromised cases).&#x000a0;A recent study indicates that administering oseltamivir early in hospitalized children led to reduced hospitalization duration and the likelihood of 7-day readmission, ECMO use, and mortality. These results affirm the current guidelines advocating oseltamivir utilization in hospitalized children with influenza.<xref ref-type="bibr" rid="article-26358.r16">[16]</xref></p>
        <p><bold>Older patients: </bold>No dose adjustments are needed for older adults in treatment and prevention with oseltamivir, considering drug exposure and tolerability.</p>
      </sec>
      <sec id="article-26358.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Oseltamivir is generally well-tolerated.<xref ref-type="bibr" rid="article-26358.r17">[17]</xref>&#x000a0;The most common side effects&#x000a0;include nausea (up to 10%), vomiting (2% to 15%), abdominal pain, diarrhea, headache, insomnia, and vertigo. Vomiting is the most frequently reported side effect in children (16% of children aged 1 to 12).<xref ref-type="bibr" rid="article-26358.r18">[18]</xref></p>
        <p>Other&#x000a0;adverse&#x000a0;effects occurring less than 1% of the time include conjunctivitis, epistaxis, allergy, arrhythmia, GI bleeding, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, confusion, seizures, and neuropsychiatric events.<xref ref-type="bibr" rid="article-26358.r6">[6]</xref><xref ref-type="bibr" rid="article-26358.r19">[19]</xref><xref ref-type="bibr" rid="article-26358.r20">[20]</xref></p>
        <p>Cutaneous adverse drug reactions like erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis have also been reported.<xref ref-type="bibr" rid="article-26358.r21">[21]</xref><xref ref-type="bibr" rid="article-26358.r22">[22]</xref><xref ref-type="bibr" rid="article-26358.r23">[23]</xref></p>
        <p>Serum aminotransferase elevations&#x000a0;have been reported in 2% of&#x000a0;clinical trials,&#x000a0;but&#x000a0;enzyme elevation in&#x000a0;patients was transient and asymptomatic.&#x000a0;The mechanism of hepatotoxicity is&#x000a0;thought to be immunoallergic. Rare cases of liver injury and jaundice have been reported, but influenza infection can also lead to&#x000a0;serum enzyme elevations and jaundice. Consequently, the likelihood score is&#x000a0;D (possible rare cause of clinically apparent liver injury).<xref ref-type="bibr" rid="article-26358.r24">[24]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Influenza&#x000a0;antiviral medications may decrease the efficacy of LAIV4 (live attenuated influenza vaccine) if&#x000a0;administered within 48 hours to 14 days after LAIV4.<xref ref-type="bibr" rid="article-26358.r25">[25]</xref>&#x000a0;Oseltamivir is an ester prodrug, and&#x000a0;oseltamivir carboxylate contributes to the antiviral activity. Hydrolytic activation is mediated&#x000a0;by human carboxylesterase (HCE) 1.&#x000a0;In the presence of clopidogrel, the hydrolysis of oseltamivir&#x000a0;is inhibited, leading to reduced antiviral efficacy.<xref ref-type="bibr" rid="article-26358.r26">[26]</xref><xref ref-type="bibr" rid="article-26358.r27">[27]</xref></p>
      </sec>
      <sec id="article-26358.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Known allergies or hypersensitivities to the drug or&#x000a0;excipients&#x000a0;are a contraindication to using oseltamivir. Cases of anaphylaxis have been reported.<xref ref-type="bibr" rid="article-26358.r28">[28]</xref></p>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Commercially available oral suspension of oseltamivir contains sorbitol and saccharin sodium and should be used cautiously in patients with hereditary fructose intolerance.<xref ref-type="bibr" rid="article-26358.r29">[29]</xref></p>
          </list-item>
          <list-item>
            <p>Since the suspension contains sodium benzoate, watch for gasping syndrome in neonates.<xref ref-type="bibr" rid="article-26358.r30">[30]</xref></p>
          </list-item>
          <list-item>
            <p>Oseltamivir should not be used in patients with influenza illnesses due to strains confirmed as resistant to oseltamivir. In addition, it should not be used for diseases caused by organisms other than influenza viruses.<xref ref-type="bibr" rid="article-26358.r7">[7]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26358.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Repeat RT-PCR or viral culture can determine the viral load in&#x000a0;critically ill patients. Neuropsychiatric events, including self-injury, confusion, and delirium, should be monitored, especially in children; reports of these events in children primarily occur in Japan and have also had correlations with fatalities.<xref ref-type="bibr" rid="article-26358.r31">[31]</xref>&#x000a0;The influenza risk assessment tool is a systematic approach for&#x000a0;evaluating&#x000a0;and&#x000a0;monitoring&#x000a0;threats by influenza viruses.<xref ref-type="bibr" rid="article-26358.r32">[32]</xref></p>
      </sec>
      <sec id="article-26358.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Oseltamivir is generally very well tolerated and has few drug interactions. Multiple animal toxicity studies, pre-marketing, and post-marketing of oseltamivir have indicated respiratory suppression resulting from central nervous system suppression, hypothermia, hypoactivity, and sudden death. This adverse event correlates with sudden-onset-type neuropsychiatric reactions in human patients (especially children from Japan), but no definitive link has been established.<xref ref-type="bibr" rid="article-26358.r33">[33]</xref>&#x000a0;The oseltamivir-induced liver injury&#x000a0;requires discontinuation of the drug and avoidance of reexposure.&#x000a0;Most patients recover&#x000a0;after discontinuation of oseltamivir&#x000a0;without specific&#x000a0;interventions.<xref ref-type="bibr" rid="article-26358.r24">[24]</xref></p>
      </sec>
      <sec id="article-26358.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Oseltamivir is used worldwide for treating and preventing influenza illness, both confirmed and suspected cases.<xref ref-type="bibr" rid="article-26358.r6">[6]</xref>&#x000a0;Consequently, clinicians&#x000a0;should&#x000a0;know the correct indications and uses of oseltamivir as guided by existing scientific evidence. The IDSA (Infectious Diseases Society of America) guidelines&#x000a0;recommend oseltamivir&#x000a0;as&#x000a0;a first-line drug therapy for influenza.<xref ref-type="bibr" rid="article-26358.r34">[34]</xref>&#x000a0;The IDSA suggests that&#x000a0;clinicians consider extended treatment in&#x000a0;patients with immunocompromised conditions or severe lower respiratory tract&#x000a0;involvement&#x000a0;(acute respiratory distress syndrome or pneumonia).&#x000a0;</p>
        <p>If influenza is suspected&#x000a0;during the viral season in any patient with chronic conditions or severe disease requiring hospitalization, the treating clinician must initiate oseltamivir treatment immediately, regardless of the duration of symptoms.<xref ref-type="bibr" rid="article-26358.r4">[4]</xref>&#x000a0;The&#x000a0;clinician must ensure proper specimens are promptly sent to the laboratory for testing. Pathologists and clinical microbiologists are responsible for rapid testing and confirmatory results, including susceptibility testing, to ensure the optimal duration of therapy. If an immunocompromised condition is suspected,&#x000a0;the treating clinician should consult an infectious disease specialist&#x000a0;regarding the use of oseltamivir in influenza illness in an immunocompromised patient.<xref ref-type="bibr" rid="article-26358.r35">[35]</xref></p>
        <p>In pediatric and&#x000a0;older patients and neurodevelopmentally challenged patients, the treating clinician must partner with the nursing staff and family members to prepare the proper oseltamivir that the patient will tolerate without side effects. In addition, a pharmacist must perform medication reconciliation and dispense the appropriate dosage form of oseltamivir. In an overdose, a medical toxicologist should be consulted. Intensivist and pulmonologist consultation is vital in case of&#x000a0;respiratory failure to deliver optimal&#x000a0;ventilatory support in critically ill patients.<xref ref-type="bibr" rid="article-26358.r36">[36]</xref>&#x000a0;Intentional overdose requires referral to a psychiatrist. The responsibility of the entire healthcare team, including clinicians (MDs, DOs, NPs, PAs), nurses, specialists, and pharmacists, is to adopt an interprofessional approach to maximize efficacy, minimize adverse events, and ultimately enhance patient outcomes regarding oseltamivir pharmacotherapy.</p>
      </sec>
      <sec id="article-26358.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26358&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26358">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/26358/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=26358">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-26358.s11">
        <title>References</title>
        <ref id="article-26358.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cooper</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Sutton</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Abrams</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Wailoo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nicholson</surname>
                <given-names>KG</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials.</article-title>
            <source>BMJ</source>
            <year>2003</year>
            <month>Jun</month>
            <day>07</day>
            <volume>326</volume>
            <issue>7401</issue>
            <fpage>1235</fpage>
            <pub-id pub-id-type="pmid">12791735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <collab>COMMITTEE ON INFECTIOUS DISEASES</collab>
            <article-title>Recommendations for Prevention and Control of Influenza in Children, 2017 - 2018.</article-title>
            <source>Pediatrics</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>140</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">28870977</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <collab>COMMITTEE ON INFECTIOUS DISEASES</collab>
            <article-title>Recommendations for Prevention and Control of Influenza in Children, 2021-2022.</article-title>
            <source>Pediatrics</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>148</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">34493538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fiore</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Fry</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shay</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gubareva</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bresee</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Uyeki</surname>
                <given-names>TM</given-names>
              </name>
              <collab>Centers for Disease Control and Prevention (CDC)</collab>
            </person-group>
            <article-title>Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP).</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2011</year>
            <month>Jan</month>
            <day>21</day>
            <volume>60</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-24</page-range>
            <pub-id pub-id-type="pmid">21248682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harper</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Bradley</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Englund</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>File</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Gravenstein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hayden</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>McGeer</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Neuzil</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Pavia</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Tapper</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Uyeki</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Zimmerman</surname>
                <given-names>RK</given-names>
              </name>
              <collab>Expert Panel of the Infectious Diseases Society of America</collab>
            </person-group>
            <article-title>Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America.</article-title>
            <source>Clin Infect Dis</source>
            <year>2009</year>
            <month>Apr</month>
            <day>15</day>
            <volume>48</volume>
            <issue>8</issue>
            <fpage>1003</fpage>
            <page-range>1003-32</page-range>
            <pub-id pub-id-type="pmid">19281331</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Treanor</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Hayden</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Vrooman</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Barbarash</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bettis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Riff</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kinnersley</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mills</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.</article-title>
            <source>JAMA</source>
            <year>2000</year>
            <month>Feb</month>
            <day>23</day>
            <volume>283</volume>
            <issue>8</issue>
            <fpage>1016</fpage>
            <page-range>1016-24</page-range>
            <pub-id pub-id-type="pmid">10697061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Webster</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Webby</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Influenza Virus: Dealing with a Drifting and Shifting Pathogen.</article-title>
            <source>Viral Immunol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>174</fpage>
            <page-range>174-183</page-range>
            <pub-id pub-id-type="pmid">29373086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pillai</surname>
                <given-names>VC</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Beigi</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Hankins</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hebert</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Easterling</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Zajicek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Caritis</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Venkataramanan</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Population pharmacokinetics of oseltamivir in non-pregnant and pregnant women.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>80</volume>
            <issue>5</issue>
            <fpage>1042</fpage>
            <page-range>1042-50</page-range>
            <pub-id pub-id-type="pmid">26040405</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Welliver</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Monto</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Carewicz</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Schatteman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hassman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hedrick</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Huson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Oxford</surname>
                <given-names>JS</given-names>
              </name>
              <collab>Oseltamivir Post Exposure Prophylaxis Investigator Group</collab>
            </person-group>
            <article-title>Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial.</article-title>
            <source>JAMA</source>
            <year>2001</year>
            <month>Feb</month>
            <day>14</day>
            <volume>285</volume>
            <issue>6</issue>
            <fpage>748</fpage>
            <page-range>748-54</page-range>
            <pub-id pub-id-type="pmid">11176912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beigel</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Farrar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Hayden</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Hyer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>de Jong</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Lochindarat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Nicoll</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Touch</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yuen</surname>
                <given-names>KY</given-names>
              </name>
              <collab>Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5</collab>
            </person-group>
            <article-title>Avian influenza A (H5N1) infection in humans.</article-title>
            <source>N Engl J Med</source>
            <year>2005</year>
            <month>Sep</month>
            <day>29</day>
            <volume>353</volume>
            <issue>13</issue>
            <fpage>1374</fpage>
            <page-range>1374-85</page-range>
            <pub-id pub-id-type="pmid">16192482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Simulation of the Pharmacokinetics of Oseltamivir and Its Active Metabolite in Normal Populations and Patients with Hepatic Cirrhosis Using Physiologically Based Pharmacokinetic Modeling.</article-title>
            <source>AAPS PharmSciTech</source>
            <year>2020</year>
            <month>Mar</month>
            <day>03</day>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>98</fpage>
            <pub-id pub-id-type="pmid">32128656</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kamal</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Lien</surname>
                <given-names>KY</given-names>
              </name>
              <name>
                <surname>Robson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Subramoney</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Clinch</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rayner</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Gibiansky</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Investigating clinically adequate concentrations of oseltamivir carboxylate in end-stage renal disease patients undergoing hemodialysis using a population pharmacokinetic approach.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>59</volume>
            <issue>11</issue>
            <fpage>6774</fpage>
            <page-range>6774-81</page-range>
            <pub-id pub-id-type="pmid">26282419</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dawood</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Kittikraisak</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rentz Hunt</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Suntarattiwong</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wesley</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Soto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mundhada</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Arriola</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Azziz-Baumgartner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Brummer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cabrera</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Deshmukh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ellison</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Florian</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gonzales</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kurhe</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kaoiean</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rawangban</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lindstrom</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Llajaruna</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mott</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Saha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Prakash</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mohanty</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sinthuwattanawibool</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tinoco</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Incidence of influenza during pregnancy and association with pregnancy and perinatal outcomes in three middle-income countries: a multisite prospective longitudinal cohort study.</article-title>
            <source>Lancet Infect Dis</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>97</fpage>
            <page-range>97-106</page-range>
            <pub-id pub-id-type="pmid">33129424</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <article-title>ACOG Committee Opinion No. 753: Assessment and Treatment of Pregnant Women With Suspected or Confirmed Influenza: Correction.</article-title>
            <source>Obstet Gynecol</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>135</volume>
            <issue>3</issue>
            <fpage>734</fpage>
            <pub-id pub-id-type="pmid">32080040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r15">
          <label>15</label>
          <element-citation publication-type="book">
            <chapter-title>Oseltamivir</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>2</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000553</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walsh</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Schnadower</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ramgopal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Association of Early Oseltamivir With Improved Outcomes in Hospitalized Children With Influenza, 2007-2020.</article-title>
            <source>JAMA Pediatr</source>
            <year>2022</year>
            <month>Nov</month>
            <day>01</day>
            <volume>176</volume>
            <issue>11</issue>
            <fpage>e223261</fpage>
            <pub-id pub-id-type="pmid">36121673</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hayden</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Atmar</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Schilling</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Poretz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Paar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Huson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mills</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza.</article-title>
            <source>N Engl J Med</source>
            <year>1999</year>
            <month>Oct</month>
            <day>28</day>
            <volume>341</volume>
            <issue>18</issue>
            <fpage>1336</fpage>
            <page-range>1336-43</page-range>
            <pub-id pub-id-type="pmid">10536125</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malosh</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Heikkinen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Whitley</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Monto</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials.</article-title>
            <source>Clin Infect Dis</source>
            <year>2018</year>
            <month>May</month>
            <day>02</day>
            <volume>66</volume>
            <issue>10</issue>
            <fpage>1492</fpage>
            <page-range>1492-1500</page-range>
            <pub-id pub-id-type="pmid">29186364</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peters</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Gravenstein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Norwood</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>De Bock</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Van Couter</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gibbens</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>von Planta</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>49</volume>
            <issue>8</issue>
            <fpage>1025</fpage>
            <page-range>1025-31</page-range>
            <pub-id pub-id-type="pmid">11555062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kang</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>Risk of neuropsychiatric adverse events associated with the use of oseltamivir: a nationwide population-based case-crossover study.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2019</year>
            <month>Feb</month>
            <day>01</day>
            <volume>74</volume>
            <issue>2</issue>
            <fpage>453</fpage>
            <page-range>453-461</page-range>
            <pub-id pub-id-type="pmid">30418537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siemieniak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yoo</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Oseltamivir induced oral-only erythema multiforme.</article-title>
            <source>Am J Emerg Med</source>
            <year>2022</year>
            <month>May</month>
            <volume>55</volume>
            <fpage>232.e1</fpage>
            <page-range>232.e1-232.e2</page-range>
            <pub-id pub-id-type="pmid">35168848</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonz&#x000e1;lez-Ramos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lamas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bell&#x000f3;n</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ruiz-Bravo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>RamIrez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lerma</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lecumberri</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Oseltamivir-induced toxic epidermal necrolysis in a patient with Cushing's disease.</article-title>
            <source>Indian J Dermatol Venereol Leprol</source>
            <year>2020</year>
            <season>Sep-Oct</season>
            <volume>86</volume>
            <issue>5</issue>
            <fpage>515</fpage>
            <page-range>515-518</page-range>
            <pub-id pub-id-type="pmid">30688217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zuo</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wen</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mei</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Oseltamivir induced Stevens-Johnson syndrome/toxic epidermal necrolysis-case report.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2019</year>
            <month>May</month>
            <volume>98</volume>
            <issue>19</issue>
            <fpage>e15553</fpage>
            <pub-id pub-id-type="pmid">31083216</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r24">
          <label>24</label>
          <element-citation publication-type="book">
            <chapter-title>Oseltamivir</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>6</month>
            <day>22</day>
            <pub-id pub-id-type="pmid">31643592</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grohskopf</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Sokolow</surname>
                <given-names>LZ</given-names>
              </name>
              <name>
                <surname>Broder</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Walter</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Fry</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Jernigan</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 Influenza Season.</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2018</year>
            <month>Aug</month>
            <day>24</day>
            <volume>67</volume>
            <issue>3</issue>
            <fpage>1</fpage>
            <page-range>1-20</page-range>
            <pub-id pub-id-type="pmid">30141464</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>LeCluyse</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>You</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Akhlaghi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>319</volume>
            <issue>3</issue>
            <fpage>1477</fpage>
            <page-range>1477-84</page-range>
            <pub-id pub-id-type="pmid">16966469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Merali</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Par&#x000e9;</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect.</article-title>
            <source>Drug Metabol Drug Interact</source>
            <year>2014</year>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>143</fpage>
            <page-range>143-51</page-range>
            <pub-id pub-id-type="pmid">24988246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hirschfeld</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Renkl</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scharffetter-Kochanek</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Anaphylaxis after Oseltamivir (Tamiflu) therapy in a patient with sensitization to star anise and celery-carrot-mugwort-spice syndrome.</article-title>
            <source>Allergy</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>63</volume>
            <issue>2</issue>
            <fpage>243</fpage>
            <page-range>243-4</page-range>
            <pub-id pub-id-type="pmid">18186817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Sarma</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Hereditary fructose intolerance: A comprehensive review.</article-title>
            <source>World J Clin Pediatr</source>
            <year>2022</year>
            <month>Jul</month>
            <day>09</day>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>321</fpage>
            <page-range>321-329</page-range>
            <pub-id pub-id-type="pmid">36052111</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <collab>Centers for Disease Control (CDC)</collab>
            <article-title>Neonatal deaths associated with use of benzyl alcohol--United States.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>1982</year>
            <month>Jun</month>
            <day>11</day>
            <volume>31</volume>
            <issue>22</issue>
            <fpage>290</fpage>
            <page-range>290-1</page-range>
            <pub-id pub-id-type="pmid">6810084</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ueda</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Umetsu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Abe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nakayama</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Kinosada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Analysis of Neuropsychiatric Adverse Events in Patients Treated with Oseltamivir in Spontaneous Adverse Event Reports.</article-title>
            <source>Biol Pharm Bull</source>
            <year>2015</year>
            <volume>38</volume>
            <issue>10</issue>
            <fpage>1638</fpage>
            <page-range>1638-44</page-range>
            <pub-id pub-id-type="pmid">26424023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trock</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Cox</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <article-title>Development of Framework for Assessing Influenza Virus Pandemic Risk.</article-title>
            <source>Emerg Infect Dis</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>21</volume>
            <issue>8</issue>
            <fpage>1372</fpage>
            <page-range>1372-8</page-range>
            <pub-id pub-id-type="pmid">26196098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Toovey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Prinssen</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Rayner</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Thakrar</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Dutkowski</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Koerner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sirzen-Zelenskaya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Britschgi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bansod</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Donner</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review.</article-title>
            <source>Adv Ther</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>29</volume>
            <issue>10</issue>
            <fpage>826</fpage>
            <page-range>826-48</page-range>
            <pub-id pub-id-type="pmid">23054689</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uyeki</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Bradley</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Englund</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>File</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Fry</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Gravenstein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hayden</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Harper</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Hirshon</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Ison</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Knight</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>McGeer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Riley</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Wolfe</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Pavia</surname>
                <given-names>AT</given-names>
              </name>
            </person-group>
            <article-title>Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.</article-title>
            <source>Clin Infect Dis</source>
            <year>2019</year>
            <month>Mar</month>
            <day>05</day>
            <volume>68</volume>
            <issue>6</issue>
            <fpage>895</fpage>
            <page-range>895-902</page-range>
            <pub-id pub-id-type="pmid">30834445</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chik</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Shing</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tam</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Yuen</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Oseltamivir prophylaxis during the influenza season in a paediatric cancer centre: prospective observational study.</article-title>
            <source>Hong Kong Med J</source>
            <year>2004</year>
            <month>Apr</month>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>103</fpage>
            <page-range>103-6</page-range>
            <pub-id pub-id-type="pmid">15075430</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26358.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Sullivan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martin-Loeches</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Influenza management with new therapies.</article-title>
            <source>Curr Opin Pulm Med</source>
            <year>2020</year>
            <month>May</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>215</fpage>
            <page-range>215-221</page-range>
            <pub-id pub-id-type="pmid">32068576</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
